Logo image of RANI

RANI THERAPEUTICS HOLDINGS-A (RANI) Stock Fundamental Analysis

NASDAQ:RANI - Nasdaq - US7530181004 - Common Stock - Currency: USD

0.5139  -0.01 (-1.19%)

Fundamental Rating

0

Taking everything into account, RANI scores 0 out of 10 in our fundamental rating. RANI was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of RANI have multiple concerns. RANI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RANI has reported negative net income.
In the past year RANI has reported a negative cash flow from operations.
RANI had negative earnings in each of the past 5 years.
In the past 5 years RANI always reported negative operating cash flow.
RANI Yearly Net Income VS EBIT VS OCF VS FCFRANI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RANI's Return On Assets of -123.52% is on the low side compared to the rest of the industry. RANI is outperformed by 80.00% of its industry peers.
Industry RankSector Rank
ROA -123.52%
ROE N/A
ROIC N/A
ROA(3y)-56.31%
ROA(5y)-39.33%
ROE(3y)-617.95%
ROE(5y)-378.96%
ROIC(3y)N/A
ROIC(5y)N/A
RANI Yearly ROA, ROE, ROICRANI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RANI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RANI Yearly Profit, Operating, Gross MarginsRANI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

0

2. Health

2.1 Basic Checks

RANI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RANI has more shares outstanding
Compared to 5 years ago, RANI has more shares outstanding
The debt/assets ratio for RANI is higher compared to a year ago.
RANI Yearly Shares OutstandingRANI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
RANI Yearly Total Debt VS Total AssetsRANI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

RANI has an Altman-Z score of -12.32. This is a bad value and indicates that RANI is not financially healthy and even has some risk of bankruptcy.
RANI has a Altman-Z score of -12.32. This is in the lower half of the industry: RANI underperforms 74.36% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.32
ROIC/WACCN/A
WACC13%
RANI Yearly LT Debt VS Equity VS FCFRANI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

RANI has a Current Ratio of 0.88. This is a bad value and indicates that RANI is not financially healthy enough and could expect problems in meeting its short term obligations.
RANI has a Current ratio of 0.88. This is amonst the worse of the industry: RANI underperforms 86.15% of its industry peers.
A Quick Ratio of 0.88 indicates that RANI may have some problems paying its short term obligations.
RANI has a worse Quick ratio (0.88) than 78.97% of its industry peers.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.88
RANI Yearly Current Assets VS Current LiabilitesRANI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.26% over the past year.
Measured over the past years, RANI shows a small growth in Revenue. The Revenue has been growing by 0.96% on average per year.
EPS 1Y (TTM)23.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-27.7%
Revenue growth 5Y0.96%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RANI will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.84% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.16%
EPS Next 2Y15.25%
EPS Next 3Y19.72%
EPS Next 5Y11.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RANI Yearly Revenue VS EstimatesRANI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2024 2025 2028 2029 2030 2031 2032 100M 200M 300M 400M
RANI Yearly EPS VS EstimatesRANI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RANI. In the last year negative earnings were reported.
Also next year RANI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RANI Price Earnings VS Forward Price EarningsRANI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RANI Per share dataRANI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as RANI's earnings are expected to grow with 19.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.25%
EPS Next 3Y19.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RANI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RANI THERAPEUTICS HOLDINGS-A

NASDAQ:RANI (6/17/2025, 8:11:34 PM)

0.5139

-0.01 (-1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners9.9%
Inst Owner Change-5.18%
Ins Owners2.17%
Ins Owner Change0%
Market Cap29.57M
Analysts84
Price Target7.96 (1448.94%)
Short Float %12.84%
Short Ratio6.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.69%
Min EPS beat(2)-7.31%
Max EPS beat(2)-6.08%
EPS beat(4)2
Avg EPS beat(4)3.59%
Min EPS beat(4)-7.31%
Max EPS beat(4)19.26%
EPS beat(8)5
Avg EPS beat(8)0.42%
EPS beat(12)9
Avg EPS beat(12)8.73%
EPS beat(16)13
Avg EPS beat(16)17.25%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-29.09%
PT rev (3m)-31.75%
EPS NQ rev (1m)-12.5%
EPS NQ rev (3m)-20.83%
EPS NY rev (1m)0%
EPS NY rev (3m)2.68%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-99.96%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.64
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.02
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -123.52%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.31%
ROA(5y)-39.33%
ROE(3y)-617.95%
ROE(5y)-378.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.2%
Cap/Sales 25.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.88
Altman-Z -12.32
F-Score3
WACC13%
ROIC/WACCN/A
Cap/Depr(3y)156.71%
Cap/Depr(5y)155.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
EPS Next Y9.16%
EPS Next 2Y15.25%
EPS Next 3Y19.72%
EPS Next 5Y11.84%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-27.7%
Revenue growth 5Y0.96%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.88%
EBIT Next 3Y-5.54%
EBIT Next 5Y14.98%
FCF growth 1Y32.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.56%
OCF growth 3YN/A
OCF growth 5YN/A